

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/22/2014; Page 1

	Estradiol 0.2 mg, Estriol 0.8 mg Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 005 501
--	--	-----	-----------

# SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC#	Supplier	Lot Number	Expiry Date
Estradiol 1% Stock Powder Blend †	2.000	g				
Estriol (Micronized), USP	0.080	g				
Medisca CapsuBlend <sup>TM</sup> -H	TBD					
Sodium Chloride, USP	As needed					
† Estradiol 1% Stock Powder Blend			<b>©</b>			
Estradiol (Micronized), USP	TBD					
Medisca CapsuBlend™-H	q.s. to 10.00	g		)*		

# **SPECIAL PREPARATORY CONSIDERATIONS**

ingredient-specific information		
Light sensitive (protect from lig	ght whenever possible):	Estradiol
Hygroscopic (protect from moi.	sture whenever possible):	Estradiol, CapsuBlend <sup>TM</sup> -H
Suggested Preparatory Guidelines		
Processing Error /	To account for processing error	considerations during preparation, it is suggested to
<u>Testing Considerations</u> :	measure an additional 5 to 9% of	the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab c should always be worn.	oat, disposable gloves, eyewear and face-masks
		very small quantities of ingredients. All calculations be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/22/2014; Page 2

	Estradiol 0.2 mg, Estriol 0.8 mg Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 005 501
--	---	-----	-----------

# **SUGGESTED PREPARATION (for 100 Size #1 Capsules)**

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Estradiol 1% Stock Powder Blend † §	2.000	g			
Estriol (Micronized), USP	0.080	g			
Medisca CapsuBlend™-H §	TBD		(8)		
Sodium Chloride, USP	As needed	_			
			), CO.		
† Estradiol 1% Stock Powder Blend		5			
Estradiol (Micronized), USP §	TBD		7		
Medisca CapsuBlend <sup>TM</sup> -H §	q.s. to 10.00	g			

<sup>\*</sup> Takes into account increased batch size conversions and density conversions, if required.

<sup>§</sup> Weigh / measure just prior to use.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/22/2014; Page 3

	ggeste ormu		FIN	F 005 501
		Preparatory Instruction		
1.	Ing	gredient quantification:		
	A.	Determine the potency of Estradiol based on the certificate of analysis:		
				100%
		MINUS		
		Water Content (from certificate of analysis)	-	%
		DIVIDED BY		100
		EQUALS		
		Quantity of water free Estradiol, in decimal	-	
		MULTIPLY BY		
		Assay on anhydrous basis result (from certificate of analysis)	-	%
		DIVIDED BY		100
		EQUALS		
		i. Potency of Estradiol, in decimal	-	
2.	Ing	gredient quantification:		
	A.	Determine the quantity of Estradiol required to make an Estradiol 1% Stock Powder Blen	d, bato	ch size (10 g).
		Quantity of Estradiol required for the Stock Powder Blend		0.100 g
		DIVIDED BY		
		Potency of Estradiol in decimal (Step 1Ai)	_	
		EQUALS		
		i Quantity of Estradiol needed for the stock powder blend		σ



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/22/2014; Page 4

_	gested Commula Estradiol 0.2 mg, Estriol 0.8 mg Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 005 501
3.	† Estradiol 1% Stock Powder Blend preparation:		
	A. By geometric addition, combine and mix the following ingredients together to form a hor	nogene	eous powder blend:
	-Estradiol (Micronized) (amount determined in Step 2Ai) -Medisca CapsuBlend <sup>TM</sup> -H (q.s. to 10.00 g)		
4.	Calculate the quantity of CapsuBlend <sup>TM</sup> -H required for 100 x Size #1 Capsules:		
	A. Determine the average capsule fill weight by filling and weighing <b>five</b> TARED capsules CapsuBlend <sup>TM</sup> -H. Divide the total weight by <b>5</b> to obtain <u>average</u> weight.	with th	g ( <b>A</b> )
	B. Quantity of CapsuBlend <sup>TM</sup> -H required per capsule = (A) – 0.0208 g* *quantity of Estradiol 1% Stock Powder Blend + Estriol per capsule	-	g ( <b>B</b> )
	C. Total quantity of CapsuBlend <sup>TM</sup> -H required for the batch = $(B)$ x 100 capsules	-	g (C)
	D. Quantity of CapsuBlend <sup>TM</sup> -H to weigh with processing error = (C) x $1.05 \sim 1.09$	-	g ( <b>D</b> )
5.	Powder preparation:		
	A. By geometric addition, combine and triturate the following ingredients together to form a blend:	homo	geneous powder
	-Estradiol 1% Stock Powder Blend (2.000 g <i>plus</i> processing error adjustments) -Estriol (Micronized) -CapsuBlend™-H ( <b>D</b> )		
	B. Pass the above powder mixture through a 40 or 50 mesh sieve.		
	C. Place the sieved powder mixture in a plastic bag and shake for approximately 3 minutes to	o ensu	re homogeneity.
6.	Product transfer:		
	Fill each of 100 Size #1 Capsules with the powder blend (Step 5C). Close each capsule tightly	<b>/</b> .	
	Clean each capsule by placing the capsules in a container filled with Sodium chloride, an container. Pour the container contents into a 10-mesh sieve, and allow the Sodium chloride roll the capsules on a cloth-covered surface.		
7.	Validation technique:		
	The final weight of each capsule (not including capsule shell) should fall between 90 and calculated weight (A), in accordance to USP 795 guidelines.	110%	of the theoretically



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/22/2014; Page 5

	Estradiol 0.2 mg, Estriol 0.8 mg Oral Capsules (Powder Blend, 100 x Size #1 Capsules)	FIN	F 005 501
--	---	-----	-----------

8. **Product transfer:** 

Transfer the final product into the specified dispensing container (see "Packaging Requirements").

### SUGGESTED PRESENTATION

OCECTED TRECENTATION						
Estim Beyond-Use		6 months, as per USP*.	Packa Requirem		Tightly closed, light-resistant, capsule shells and vials.	
	1	Use as directed. Do not exceed dose.	d prescribed	6	Keep at room temperature (20°C – 23°C).	
Auxiliary	2	Keep out of reach of children.		7	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.	
Labels	3	Do not take with alcohol, tranquilizers or other CNS depre		8	Keep in a dry place.	
	4	Cap tightly after use.		9	May impair mental and/or physical ability. Use care when operating a car or machinery.	
	5	Protect from light.	\ \			
Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.				nsing container as deemed necessary.		
Patient Instructions	Co	ontact your pharmacist in the event	of adverse re	actior	ns.	

\* The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.

# **REFERENCES**

1.	Capsules. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 127.
2.	Divigel. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2013: 899.
3.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 6 <sup>th</sup> Edition. American Pharmaceutical Association; 2009: 637.
4.	Estradiol. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 <sup>th</sup> Edition. London, England: The Pharmaceutical Press; 2009: 2097.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/22/2014; Page 6

Suggested Formula	FIN	F 005 501

5.	Estriol. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 <sup>th</sup> Edition. London, England: The Pharmaceutical Press; 2009: 2101.
6.	Estradiol (Monograph). In: O'Neil MJ. <i>The Merck Index 14<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #3703.
7.	Estriol (Monograph). In: O'Neil MJ. <i>The Merck Index 14<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #3707.
8.	Estradiol. In: Trissel LA. Trissel's Stability of Compounded Formulations, 4th Edition. American Pharmaceutical Association; 2009: 222.
9.	Estradiol (Monograph). <i>United States Pharmacopeia XXXVI / National Formulary 31</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2013: 3470.
10.	Estriol (Monograph). <i>United States Pharmacopeia XXXVI / National Formulary 31</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2013: 3486.
11.	Estradiol. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional</i> , 26 <sup>th</sup> Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 1382.
12.	USP <795>. United States Pharmacopeia XXXVI / National Formulary 31. Rockville, MD. US Pharmacopeial Convention, Inc. 2013: 355.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.